David Wofsy

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials
    David Wofsy
    Arthritis Immunology Unit 111R, San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Arthritis Rheum 65:1586-91. 2013
  2. doi request reprint Recent progress in conventional and biologic therapy for systemic lupus erythematosus
    David Wofsy
    Division of Rheumatology, The Rosalind Russell Medical Research Center for Arthritis at the University of California San Francisco, San Francisco, CA 94143, USA
    Ann Rheum Dis 72:ii66-8. 2013
  3. doi request reprint Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions
    David Wofsy
    University of California, San Francisco, USA
    Arthritis Rheum 64:3660-5. 2012
  4. ncbi request reprint Trials and tribulations in systemic lupus erythematosus
    David Wofsky
    Division of Rheumatology, Department of Medicine, Rosalind Russell Medical Research Center, University of California, San Francisco, California 94121, USA
    Bull NYU Hosp Jt Dis 68:175-8. 2010
  5. doi request reprint Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide
    Maria Dall'Era
    University of California, San Francisco, 94143 0633, USA
    Arthritis Care Res (Hoboken) 63:351-7. 2011
  6. ncbi request reprint Biologic therapy for systemic lupus erythematosus
    Maria Dall'Era
    Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA
    Discov Med 9:20-3. 2010
  7. doi request reprint Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis
    Mary Anne Dooley
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    N Engl J Med 365:1886-95. 2011
  8. doi request reprint Systemic lupus erythematosus clinical trials-an interim analysis
    Maria Dall'Era
    Division of Rheumatology, University of California, San Francisco, CA 94121, USA
    Nat Rev Rheumatol 5:348-51. 2009
  9. pmc Regulatory T cells as therapeutic targets in rheumatoid arthritis
    Jonathan H Esensten
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
    Nat Rev Rheumatol 5:560-5. 2009
  10. pmc A quality indicator set for systemic lupus erythematosus
    Jinoos Yazdany
    Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA 94143 0920, USA
    Arthritis Rheum 61:370-7. 2009

Collaborators

Detail Information

Publications11

  1. doi request reprint Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials
    David Wofsy
    Arthritis Immunology Unit 111R, San Francisco VA Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Arthritis Rheum 65:1586-91. 2013
    ....
  2. doi request reprint Recent progress in conventional and biologic therapy for systemic lupus erythematosus
    David Wofsy
    Division of Rheumatology, The Rosalind Russell Medical Research Center for Arthritis at the University of California San Francisco, San Francisco, CA 94143, USA
    Ann Rheum Dis 72:ii66-8. 2013
    ..These advances in the use of conventional therapies provide an important frame of reference for evaluating the novel biologic therapies that are expected to emerge in the near future...
  3. doi request reprint Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions
    David Wofsy
    University of California, San Francisco, USA
    Arthritis Rheum 64:3660-5. 2012
    ..In so doing, we sought to determine which criteria are most sensitive to differences among treatment groups and to further examine the potential of abatacept in lupus nephritis...
  4. ncbi request reprint Trials and tribulations in systemic lupus erythematosus
    David Wofsky
    Division of Rheumatology, Department of Medicine, Rosalind Russell Medical Research Center, University of California, San Francisco, California 94121, USA
    Bull NYU Hosp Jt Dis 68:175-8. 2010
    ..These advances provide an important backdrop for recent trials designed to determine the potential value of several promising biologic therapies for SLE...
  5. doi request reprint Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide
    Maria Dall'Era
    University of California, San Francisco, 94143 0633, USA
    Arthritis Care Res (Hoboken) 63:351-7. 2011
    ..To this end, we utilized data from the Aspreva Lupus Management Study to identify possible baseline and early predictors of renal response to mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide (CYC)...
  6. ncbi request reprint Biologic therapy for systemic lupus erythematosus
    Maria Dall'Era
    Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA
    Discov Med 9:20-3. 2010
    ..This encouraging news follows several disappointments in trials of other biologic therapies and provides a timely moment to reflect on where we stand, what we have learned, and what may lie ahead...
  7. doi request reprint Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis
    Mary Anne Dooley
    Department of Medicine, University of North Carolina, Chapel Hill, USA
    N Engl J Med 365:1886-95. 2011
    ..Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis...
  8. doi request reprint Systemic lupus erythematosus clinical trials-an interim analysis
    Maria Dall'Era
    Division of Rheumatology, University of California, San Francisco, CA 94121, USA
    Nat Rev Rheumatol 5:348-51. 2009
    ..This article provides an analysis of the major clinical trials in SLE, and offers an interpretation of the results that could illuminate the path forward...
  9. pmc Regulatory T cells as therapeutic targets in rheumatoid arthritis
    Jonathan H Esensten
    Diabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA
    Nat Rev Rheumatol 5:560-5. 2009
    ..Thus, cell-based therapy with TREG has the potential to produce durable disease remission in patients with RA...
  10. pmc A quality indicator set for systemic lupus erythematosus
    Jinoos Yazdany
    Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA 94143 0920, USA
    Arthritis Rheum 61:370-7. 2009
    ..To systematically develop a quality indicator (QI) set for systemic lupus erythematosus (SLE)...
  11. ncbi request reprint Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic diseases
    David I Daikh
    Arthritis Unit 111R, Department of Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121, USA
    Arthritis Rheum 55:322-4. 2006